Stability of Amorphous Pharmaceutical Solids: Crystal Growth Mechanisms and Effect of Polymer Additives
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
We review recent progress toward understanding and enhancing the stability of amorphous pharmaceutical solids against crystallization. As organic liquids are cooled to become glasses, fast modes of crystal growth can emerge. One such growth mode, the glass-to-crystal or GC mode, occurs in the bulk, and another exists at the free surface, both leading to crystal growth much faster than predicted by theories that assume diffusion defines the kinetic barrier of crystallization. These phenomena have received different explanations, and we propose that GC growth is a solid-state transformation enabled by local mobility in glasses and that fast surface crystal growth is facilitated by surface molecular mobility. In the second part, we review recent findings concerning the effect of polymer additives on crystallization in organic glasses. Low-concentration polymer additives can strongly inhibit crystal growth in the bulk of organic glasses, while having weaker effect on surface crystal growth. Ultra-thin polymer coatings can inhibit surface crystallization. Recent work has shown the importance of molecular weight for crystallization inhibitors of organic glasses, besides “direct intermolecular interactions” such as hydrogen bonding. Relative to polyvinylpyrrolidone, the VP dimer is far less effective in inhibiting crystal growth in amorphous nifedipine. Further work is suggested for better understanding of crystallization of amorphous organic solids and the prediction of their stability.
Authors and Affiliations
Ye Sun, Lei Zhu, Tian Wu, Ting Cai, Erica M. Gunn, Lian Yu
Keywords
Related Articles
- EP ID EP681222
- DOI 10.1208/s12248-012-9345-6
- Views 47
- Downloads 0
Developmental toxicity of prenatal exposure to toluene
Organic solvents have become ubiquitous in our environment and are essential for industry. Many women of reproductive age are incresingly exposed to solvents such as toluene in occupational settings (ie, long-term, lowco...
US pharmacopeia council of experts 2005–2010: Work plans, new revision approaches, and other enhancements
The United States Pharmacopeial Convention (the USP Convention), which meets at 5-year intervals, last convened in 2005. At that meeting, the convention membership elected a new Council of Experts for the 2005–20...
Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor
The online version of this article (doi:10.1208/s12248-011-9254-0) contains supplementary material, which is available to authorized users.
Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model
This study aimed to develop a joint population pharmacokinetic model for an antipsychotic agent in development ({"type":"entrez-protein","attrs":{"text":"S33138","term_id":"423514","term_text":"pir||S33138"}} S33138) and...
Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment
The administration of human biotherapeutics is often associated with a higher incidence of immunogenicity in preclinical species. The presence of anti-drug antibodies (ADAs) in the test samples can affect the accurate me...